<p>AstraZeneca's Chief Executive said on Tuesday that the results of a study showing its Covid-19 vaccine had little effect against the mild disease were concerning but stressed that it should work against severe forms.</p>.<p>"It is, of course, a concern," Pascal Soriot said of the study at a World Health Organization meeting. "Having said that the patients in the study were patients with mild disease and we believe the vaccine should still protect against severe disease."</p>.<p>AstraZeneca is a major supplier to a WHO-backed vaccine-sharing scheme called COVAX.</p>
<p>AstraZeneca's Chief Executive said on Tuesday that the results of a study showing its Covid-19 vaccine had little effect against the mild disease were concerning but stressed that it should work against severe forms.</p>.<p>"It is, of course, a concern," Pascal Soriot said of the study at a World Health Organization meeting. "Having said that the patients in the study were patients with mild disease and we believe the vaccine should still protect against severe disease."</p>.<p>AstraZeneca is a major supplier to a WHO-backed vaccine-sharing scheme called COVAX.</p>